Now showing items 1-5 of 5

    • Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. 

      Yap, TA; Macklin-Doherty, A; Popat, S (2017-01)
      The majority of patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) respond to first-line EGFR tyrosine kinase inhibitors (TKIs), but nearly all inevitably acquire resistance and ...
    • DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade. 

      Touat, M; Sourisseau, T; Dorvault, N; Chabanon, RM; Garrido, M; Morel, D; Krastev, DB; Bigot, L; Adam, J; Frankum, JR; Durand, S; Pontoizeau, C; Souquère, S; Kuo, M-S; Sauvaigo, S; Mardakheh, F; Sarasin, A; Olaussen, KA; Friboulet, L; Bouillaud, F; Pierron, G; Ashworth, A; Lombès, A; Lord, CJ; Soria, J-C; Postel-Vinay, S (2018-04)
      Synthetic lethality is an efficient mechanism-based approach to selectively target DNA repair defects. Excision repair cross-complementation group 1 (ERCC1) deficiency is frequently found in non-small-cell lung cancer ...
    • Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach. 

      Pender, A; Garcia-Murillas, I; Rana, S; Cutts, RJ; Kelly, G; Fenwick, K; Kozarewa, I; Gonzalez de Castro, D; Bhosle, J; O'Brien, M; Turner, NC; Popat, S; Downward, J (2015-01)
      Droplet digital PCR (ddPCR) can be used to detect low frequency mutations in oncogene-driven lung cancer. The range of KRAS point mutations observed in NSCLC necessitates a multiplex approach to efficient mutation detection ...
    • Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. 

      Gomes, F; Wong, M; Battisti, NML; Kordbacheh, T; Kiderlen, M; Greystoke, A; Luciani, A
      Immunotherapy with checkpoint inhibitors against programmed cell death receptor (PD-1) and programmed cell death ligand (PD-L1) has been implemented in the treatment pathway of patients with non-small cell lung cancer ...
    • PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. 

      Chabanon, RM; Muirhead, G; Krastev, DB; Adam, J; Morel, D; Garrido, M; Lamb, A; Hénon, C; Dorvault, N; Rouanne, M; Marlow, R; Bajrami, I; Cardeñosa, ML; Konde, A; Besse, B; Ashworth, A; Pettitt, SJ; Haider, S; Marabelle, A; Tutt, AN; Soria, J-C; Lord, CJ; Postel-Vinay, S (2019-03)
      The cyclic GMP-AMP synthase/stimulator of IFN genes (cGAS/STING) pathway detects cytosolic DNA to activate innate immune responses. Poly(ADP-ribose) polymerase inhibitors (PARPi) selectively target cancer cells with DNA ...